The UK and US have forged a major commercial pact that will keep no duties on British medicine products being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the public health system. This pledge guarantees that import taxes on these vital products will remain at zero for a duration of the next three years.
This deal follows earlier statements to dramatically increase tariffs on patented drug imports, with increases mentioned as high as double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue balance to American-British medicine commerce," a release noted.
Trade Significance
Pharmaceuticals are one of the Britain's largest goods shipped to the US, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This figure represented 17.4% of total UK exports in that span.
"This deal safeguards employment, boosts capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Detailed UK Commitments
The deal includes several key commitments from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Previously, repayments exceeded 20%.
Recent Tensions
The deal follows a long-running row between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by claims that US consumers were paying a premium for the same drugs than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while major investments have been directed toward projects in the United States.
One official stated that the NHS must spend more on treatments, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
